Anticoagulation treatment. — Competitive Intelligence Brief

Anticoagulation treatment. (Anticoagulation treatment.) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticoagulant. Area: Cardiovascular.

phase 2 Anticoagulant Vitamin K-dependent clotting factors Cardiovascular Small molecule

Target snapshot

Anticoagulation treatment. (Anticoagulation treatment.) — Samsung Medical Center. Anticoagulation via inhibition of vitamin K-dependent clotting factors

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anticoagulation treatment. TARGET	Anticoagulation treatment.	Samsung Medical Center	phase 2	Anticoagulant	Vitamin K-dependent clotting factors
Acetylsalicylic Acid + clopidogrel + acenocoumarol	Acetylsalicylic Acid + clopidogrel + acenocoumarol	Hospital Universitari Vall d'Hebron Research Institute	marketed	Antiplatelet agent + Anticoagulant combination	Platelet cyclooxygenase (COX), P2Y12 receptor, Vitamin K-dependent clotting factors
Nadroparin Calcium and Warfarin	Nadroparin Calcium and Warfarin	Shanghai Zhongshan Hospital	marketed	Anticoagulant combination (low-molecular-weight heparin + vitamin K antagonist)	Antithrombin III (nadroparin); Vitamin K-dependent clotting factors II, VII, IX, X (warfarin)
Warfarin and Enoxaparin	Warfarin and Enoxaparin	Cook County Health	marketed	Anticoagulant combination (vitamin K antagonist + low-molecular-weight heparin)	Vitamin K-dependent clotting factors (warfarin); Factor Xa and Factor IIa (enoxaparin)
aPCC, aPCC + TXA	aPCC, aPCC + TXA	Oslo University Hospital	marketed	Prothrombin complex concentrate with antifibrinolytic agent	Vitamin K-dependent clotting factors (II, VII, IX, X); plasminogen
nadroparin calcium-warfarin sequential anticoagulation	nadroparin calcium-warfarin sequential anticoagulation	Qilu Hospital of Shandong University	marketed	Anticoagulant combination (LMWH + vitamin K antagonist)	Factor Xa, thrombin (nadroparin); vitamin K-dependent clotting factors II, VII, IX, X (warfarin)
Warfarin vs ASA	Warfarin vs ASA	Hamilton Health Sciences Corporation	marketed	Anticoagulant (warfarin) and antiplatelet agent (aspirin)	Vitamin K-dependent clotting factors (warfarin); cyclooxygenase (aspirin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticoagulant class)

1. Fresenius Kabi · 4 drugs in this class
2. University of Sao Paulo · 3 drugs in this class
3. Beijing Anzhen Hospital · 2 drugs in this class
4. San Filippo Neri General Hospital · 2 drugs in this class
5. Yong Seog Oh · 2 drugs in this class
6. CCRF Consulting Co., Ltd. · 1 drug in this class
7. Boston Scientific Corporation · 1 drug in this class
8. Beijing Suncadia Pharmaceuticals Co., Ltd · 1 drug in this class
9. Faculty Hospital Kralovske Vinohrady · 1 drug in this class
10. Deutsches Herzzentrum Muenchen · 1 drug in this class